Calithera Biosciences - CALA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.67
  • Forecasted Upside: 522.22 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.00
▼ -0.14 (-4.46%)

This chart shows the closing price for CALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calithera Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALA

Analyst Price Target is $18.67
▲ +522.22% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Calithera Biosciences in the last 3 months. The average price target is $18.67, with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 522.22% upside from the last price of $3.00.

This chart shows the closing price for CALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Calithera Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2022HC WainwrightUpgradeNeutral ➝ Buy$8.00Low
8/16/2022SVB LeerinkBoost TargetOutperform$18.00Low
5/11/2022LADENBURG THALM/SH SHLower Target$60.00 ➝ $30.00High
4/4/2022SVB LeerinkLower TargetOutperform$60.00 ➝ $40.00Medium
1/31/2022LADENBURG THALM/SH SHInitiated CoverageBuy$80.00High
1/20/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$60.00High
11/8/2021HC WainwrightDowngradeBuy ➝ NeutralMedium
11/5/2021William BlairDowngradeOutperform ➝ Market PerformHigh
8/9/2021HC WainwrightReiterated RatingBuy$80.00Low
5/10/2021HC WainwrightReiterated RatingBuy$80.00High
1/5/2021Smith Barney CitigroupLower Target$200.00 ➝ $100.00N/A
1/5/2021HC WainwrightLower TargetBuy$190.00 ➝ $80.00N/A
1/5/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$140.00 ➝ $40.00N/A
8/11/2020SVB LeerinkLower TargetOutperform$180.00 ➝ $140.00High
6/2/2020William BlairReiterated RatingBuyMedium
5/11/2020CitigroupBoost TargetBuy$140.00 ➝ $200.00High
5/8/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $190.00High
3/27/2020CitigroupLower TargetBuy$160.00 ➝ $140.00High
3/27/2020Jefferies Financial GroupInitiated CoverageBuy$120.00High
3/11/2020SVB LeerinkReiterated RatingOutperformHigh
11/27/2019HC WainwrightInitiated CoverageBuy$140.00High
11/19/2019HC WainwrightInitiated CoverageBuy$140.00High
8/9/2019CitigroupSet TargetHold$160.00Medium
6/21/2019William BlairReiterated RatingBuyLow
5/30/2019CitigroupReiterated RatingBuy$200.00Medium
4/6/2018SVB LeerinkReiterated RatingOutperformMedium
2/16/2018CitigroupUpgradeNeutral ➝ Buy$139.00 ➝ $280.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

-0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/10/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
4/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/8/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
10/6/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Calithera Biosciences logo
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.00
Low: $2.99
High: $3.15

50 Day Range

MA: $3.60
Low: $2.78
High: $4.88

52 Week Range

Now: $3.00
Low: $2.30
High: $43.00

Volume

2,975 shs

Average Volume

125,611 shs

Market Capitalization

$14.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Calithera Biosciences?

The following sell-side analysts have issued reports on Calithera Biosciences in the last year: HC Wainwright, LADENBURG THALM/SH SH, StockNews.com, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for CALA.

What is the current price target for Calithera Biosciences?

3 Wall Street analysts have set twelve-month price targets for Calithera Biosciences in the last year. Their average twelve-month price target is $18.67, suggesting a possible upside of 522.2%. LADENBURG THALM/SH SH has the highest price target set, predicting CALA will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Calithera Biosciences in the next year.
View the latest price targets for CALA.

What is the current consensus analyst rating for Calithera Biosciences?

Calithera Biosciences currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CALA will outperform the market and that investors should add to their positions of Calithera Biosciences.
View the latest ratings for CALA.

What other companies compete with Calithera Biosciences?

How do I contact Calithera Biosciences' investor relations team?

Calithera Biosciences' physical mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 870-1000 and its investor relations email address is [email protected] The official website for Calithera Biosciences is www.calithera.com. Learn More about contacing Calithera Biosciences investor relations.